FREE Account Opening + No Clearing Fees
Loading...

Syngene International Ltd IPO (Syngene International IPO) Detail

July 27, 2015 - July 29, 2015

Syngene International IPO is a book built issue of Rs 550.00 crores.

Syngene International IPO bidding started from July 27, 2015 and ended on July 29, 2015. The shares got listed on BSE, NSE on August 11, 2015.

Syngene International IPO price band is set at ₹240 to ₹250 per share. The minimum lot size for an application is 60 Shares. The minimum amount of investment required by retail investors is ₹15,000.

Axis Bank Limited, Credit Suisse Securities (India) Private Limited and Jefferies India Private Limited are the book running lead managers of the Syngene International IPO, while Kfin Technologies Limited is the registrar for the issue.

Refer to Syngene International IPO RHP for detailed information.

Syngene International IPO Details

IPO Date July 27, 2015 to July 29, 2015
Listing Date August 11, 2015
Face Value ₹10 per share
Price Band ₹240 to ₹250 per share
Lot Size 60 Shares
Total Issue Size22,000,000 shares
(aggregating up to ₹550.00 Cr)
Issue Type Book Built Issue IPO
Listing At BSE, NSE

Syngene International IPO Reservation

Syngene International IPO offers 16,000,000 shares. 4,000,000 (25.00%) to QIB, 3,000,000 (18.75%) to NII, 7,000,000 (43.75%) to RII. 116,666 RIIs will receive minimum 60 shares and (sNII) and (bNII) will receive minimum 840 shares. (in case of oversubscription)

<>
Investor Category Shares OfferedMaximum Allottees
Anchor Investor Shares Offered-NA
QIB Shares Offered4,000,000 (25.00%)NA
NII (HNI) Shares Offered3,000,000 (18.75%)
Retail Shares Offered7,000,000 (43.75%)116,666
Other Shares Offered2,000,000 (12.50%)NA
Total Shares Offered16,000,000 (100%)

Syngene International IPO Lot Size

Investors can bid for a minimum of 60 shares and in multiples thereof. The below table depicts the minimum and maximum investment by retail investors and HNI in terms of shares and amount.

Application Lots Shares Amount
Retail (Min) 1 60 ₹15,000
Retail (Max) 13 780 ₹195,000
Lot Size Calculator

About Syngene International Ltd

Incorporated in 1993, Syngene International Ltd is a subsidiary of Biocon Limited ("Biocon"), a global biopharmaceutical enterprise focused on delivering affordable formulations and compounds.

Headquartered in Bengaluru, Syngene International is India-based contract research organisations ("CRO"), offering a suite of integrated, end-to-end discovery and development services for novel molecular entities ("NMEs") across industrial sectors including pharmaceutical, biotechnology, agrochemicals, consumer health, animal health, cosmetic and nutrition companies. Their services in discovery and development cover multiple domains across small molecules, large molecules, antibody-drug conjugates ("ADC") and oligonucleotides.

Syngene offer customized models as per their clients requirements. These range from a full-time equivalent ("FTE") to a fee-for-service ("FFS") model, or a combination thereof. Till Dec 31, 2014, they serviced 195 clients, ranging from multinational corporations to start-ups, including seven of the top 10 global pharmaceutical companies by sales for 2014. Company's long term clients includes global healthcare organisations Bristol-Myers Squibb Co. ("BMS"), Abbott Laboratories (Singapore) Pte. Ltd. ("Abbott") and Baxter International Inc. ("Baxter").

Company Financials

ParticularsFor the year/period ended (in Rs. Million)
31 Dec 1431 Mar 1431 Mar 1331 Mar 12
Total Income6,1757,0775,5424,182
Profit After Tax (PAT)1,1941,3481,021710

Objects of the Issue (Syngene International IPO Objectives)

The objects of the offer are to:

1. Achieve the benefits of listing the Equity Shares on the Stock Exchanges;
2. Enhance visibility and brand image among existing and potential clients; and
3. Provide liquidity to the existing shareholders.

Syngene International IPO Review (Apply)

[Dilip Davda]  

Syngene Intl Ltd -  Modest investment recommended

DISCLAIMER: No financial information whatsoever published anywhere here should be construed as an offer to buy or sell securities, or as advice to do so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on information published here. Any reader taking decisions based on any information published here does so entirely at own risk. Author has no plans to invest in this offer.

Read detail review...


Syngene International IPO Subscription Status (Bidding Detail)

The Syngene International IPO is subscribed 32.05 times on July 29, 2015 6:10:00 PM. The public issue subscribed 4.78 times in the retail category, 51.47 times in the QIB category, and 90.24 times in the NII category. Check Day by Day Subscription Details (Live Status)

CategorySubscription (times)
QIB51.47
NII90.24
Retail4.78
Others1.37
Total32.05

Syngene International IPO Prospectus

Syngene International IPO Rating

530
4.0
Rating:Rated 4.0 stars
Vote Here ...

Syngene International IPO Listing Details

Listing Date August 11, 2015
BSE Script Code 539268
NSE Symbol SYNGENE
ISIN INE398R01022
Final Issue Price ₹250 per share

Pre-Open Session - NSE Pre-Open Session - BSE

Listing Day Trading Information

Price Details
Final Issue Price
Open
Low
High
Last Trade
BSE
₹250.00
₹295.00
₹295.00
₹318.20
₹310.40
NSE
₹250.00
₹295.00
₹295.00
₹318.50
₹310.55

Check IPO Performance…

Syngene International Ltd Contact Details

Syngene International Ltd
Biocon SEZ Biocon Park,
Plot No 2 & 3 Bommasandra Inds,
Bengaluru - 560099, Karnataka
Phone: +91-80-28082808
Email: investor@syngeneintl.com
Website: http://www.syngeneintl.com

Syngene International IPO Registrar

Kfin Technologies Limited

Phone: 04067162222, 04079611000
Email: einward.ris@karvy.com
Website: https://kosmic.kfintech.com/ipostatus/

Syngene International IPO - Buy or Not

Syngene International IPO Recommendation Summary

Review By Subscribe Neutral Avoid
Brokers 9 0 1
Members 0 0 0

Read All Reviews Post Your Review Manage Reviews

Syngene International IPO FAQs

Syngene International IPO is a main-board IPO of 22,000,000 equity shares of the face value of ₹10 aggregating up to ₹550.00 Crores. The issue is priced at ₹240 to ₹250 per share. The minimum order quantity is 60 Shares.

The IPO opens on July 27, 2015, and closes on July 29, 2015.

Kfin Technologies Limited is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.

The Syngene International IPO opens on July 27, 2015 and closes on July 29, 2015.

Syngene International IPO lot size is 60 Shares, and the minimum amount required is ₹15,000.

You can apply in Syngene International IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don't offer banking services. Read more detail about apply IPO online through Zerodha, Upstox, 5Paisa, Nuvama, ICICI Bank, HDFC Bank and SBI Bank.

The finalization of Basis of Allotment for Syngene International IPO will be done on [.], and the allotted shares will be credited to your demat account by [.]. Check the Syngene International IPO allotment status.

The Syngene International IPO listing date is on August 11, 2015.
Open an Instant Account with Zerodha

Syngene International IPO Message Board

Ranked Members of Chittorgarh.com Forum  Ranked Members | Most Liked Members

Loading...

489 Comments

296. GIRISH KULKARNI |   Link |  Bookmark |September 24, 2015 1:44:08 PM
Forget trading. Call me for multibagger stocks. Two research reports monthly. I have a scrip which will be 10 bagger in my portfolio. Contact on gsk1595@rediffmail.com or 9765889870.
295. CHIRAG |   Link |  Bookmark |August 19, 2015 2:10:43 PM
Dear, I have applied for 5 Lots but not allotted any shares & not still received refund of same, can you tel me were to complaints any contact no. / mail Id
295.1. gundu anna |   Link |  Bookmark |August 25, 2015 7:42:13 AM (500+ Posts, 100+ Likes)
If you have not been allotted, don''t worry.. you will get below IPO price over a period of time.. contract research business will always have up and down... Not a great stock for long term.. Discl: don''t hold
294. peegee |   Link |  Bookmark |August 18, 2015 10:14:39 AM
At what price to sell syngene int. ??
293. BABULAL KATARIA |   Link |  Bookmark |August 14, 2015 8:04:13 PM
THE RETAIL PORTION OF THE IPO WAS OVERSUBSCRIBED TO ONLY 4.7 TIME, BUT THE COMPANY HAS NOT ALLOTTED SHARES TO THOSE INVESTORS WHO APPLY MORE THAN 6 TIME OF THE MINIMUM LOT OF SHARES I.E. 60 SHARE. I HAVE APPLY FOR 360 SHARES BUT NOT ALLOTTED ANY SHARE. WAS INFORMED BY THE KARVY OFFICE THAT RETAIL INVESTORS WERE ALLOTTED SHARES IN THE RATIO OF 16:43 AND THAT IS THE REASON FOR NOT ALLOTMENT. NOW I OBSERVED THAT THE COMPANIES ALLOTTED ONLY ONE LOT OF SHARES TO RETAIL INVESTORS IN CASE OF OVER SUBSCRIPTION.THEREFORE, NOW EVERY RETAIL INVESTOR SHOULD APPLY FOR ONLY ONE LOT OF SHARES AND DO NOT INVEST UPTO RS. 2,00,000/-.
293.1. star ipo |   Link |  Bookmark |August 14, 2015 8:10:50 PM
Agreed..if all application comes with only 1 lot then confirmed aallotment to every one sure.....
292. Prakash Barnwal |   Link |  Bookmark |August 13, 2015 7:20:44 PM
I had applied for 780 shares of Syngene International Ltd through ICICIDIRECT.COM through at cut off price. Although the allotment is made on proportionate basis, I have not been allotted any shares. What could be the reason for this and what is the remedy left for me.
292.1. BABULAL KATARIA |   Link |  Bookmark |August 14, 2015 8:16:18 PM
NEXT TIME APPLY FOR ONLY ONE LOT.
291. jimb |   Link |  Bookmark |August 13, 2015 10:21:09 AM
Pinkyji, the basis of allotment link on this website says allotment document for syngene not released yet. I''llb grateful if u can give me the exact basis of allotmentfor each category in syngene ipo. My email is jimishb at the rate gmail dot com
291.1. pinkyjain |   Link |  Bookmark |August 13, 2015 5:52:46 PM
Atleast thanks me
291.2. jimb |   Link |  Bookmark |August 14, 2015 1:14:08 PM
Thank u pinkyji..i have yet to receive complete allotment details for biocon shareholders category...
290. jimb |   Link |  Bookmark |August 12, 2015 6:27:05 PM
Basis of IPO stock allocation is published by the registrar of the issue in two weeks of IPO share bid closing date.
Why is it not out for syngene yet?
290.1. star ipo |   Link |  Bookmark |August 12, 2015 10:40:48 PM
That''s why corrupt registrars again banned for ipo
290.2. pinkyjain |   Link |  Bookmark |August 12, 2015 11:39:54 PM
They are out way back what non sense

Plz provide me with your email id
289. bangalore king |   Link |  Bookmark |August 12, 2015 3:45:14 PM (400 Posts)
Here are 10 quick facts about the company.

1. Syngene International started operations in 1993 providing contract research in chemistry and biology. It now has discovery and development service offerings across small and large molecules, DNA molecules and antibody-drug conjugates.

2. Kiran Mazumdar-Shaw is the founder of Syngene. The company was first established as a private limited company in 1993 and became a public limited entity in 2007. In 2002, 99.9% of its equity shares were transferred to Biocon Ltd, making it a subsidiary of the company.

3. Silver Leaf Oak Advisors has held a 10% stake in the company since 2014.

4. Bristol Myers Squibb, Abbott Laboratories (Singapore) Pte. Ltd and Baxter International Inc. are three of its major clients. It also has smaller clients such as Achillion Pharmaceuticals Inc., Aquinox Pharmaceuticals Inc. and Saniona AB. The total count of clients as of March this year was 221, only 5% of whom are based in India.

5. Seventy percent of its revenue comes from the top 10 clients. Bristol Myers Squibb alone contributes 30%. These clients have long-term contracts.

6. It has 400 scientists working exclusively for Bristol Myers Squibb. It also has 150 scientists for Baxter and 30 scientists for Abbott.

7. Syngene has 900,000 sq. ft of work space in Bengaluru and is also in the process of setting up a 200,000 sq. ft research centre and a manufacturing facility.

8. The contract research provider has 2,685 employees, of whom 2,122 are scientists, with an average age of less than 28 years. 24% of revenue, or Rs.200 crore, went toward employee benefits in the year ended March.

9. Syngene has so far developed monoclonal antibodies, glycoproteins, complex proteins, conjugated proteins in E. coli and Chinese hamster ovary cells.

10. Clinigene is the clinical trials subsidiary of Syngene, which accounts for less than 10% of its revenue.
288. Kumaripo |   Link |  Bookmark |August 12, 2015 10:28:02 AM
Those who want to enter syngene may enter around 250(likely to hit within a month or two)
287. M S |   Link |  Bookmark |August 11, 2015 8:39:27 PM
Refund not Credited In Bank A/c.
286. Chem cho |   Link |  Bookmark |August 11, 2015 5:52:40 PM
IPO Guru IPO Guru (2500+ Posts, 2700+ Likes)
maximum run will not be more that RS 325

it canot go above bicom shares
285. DCC |   Link |  Bookmark |August 11, 2015 5:44:03 PM
Hold or sold

What so ever

Happy Listing
284. Khushaal Bhandari |   Link |  Bookmark |August 11, 2015 2:04:10 PM
Lot of Pent-up demand & buying seen.
Retail & HNI allotment supply was soaked up easily during 10- 11 am.
283. manu |   Link |  Bookmark |August 11, 2015 1:27:23 PM
Sold share @315/ all 60 shares
282. Darsh |   Link |  Bookmark |August 11, 2015 12:03:27 PM
IT WILL GIVE GOOD RETURN IN LONG TERM, WHEN WE ARE COMPARING IT WITH "SPARC" A SUN PHARMA SUBSIDIARY (LOSS MAKING), IT IS WORTH TO HOLD UP TO Rs. 400......
281. Anil Rajani |   Link |  Bookmark |August 11, 2015 11:54:28 AM
I had applied for 1 lot in the morning on the very first day. But not alloted. What is the reason???
On what basis they allot? Does the number of lots matter???

Please guide as I do not want to miss on upcoming Alkem IPO.
281.2. Anil Rajani |   Link |  Bookmark |August 11, 2015 2:18:43 PM
Does applying for more number of lots help?
281.3. SHASHANK K S |   Link |  Bookmark |August 11, 2015 2:49:46 PM
No..
But you can increase the chances of allocation by applying in the name of your family members
280. IPOANALYSIS |   Link |  Bookmark |August 11, 2015 11:20:01 AM
SOON A PHARMA FUND WILL BUY IT. NOONE CAN GET BETTER PHARMA COMOPANY THAN THIS ONE WITH THE GROWTH POTENTIAL.

THIS STOCK IS A GEM. LOOK AT WHAT HAPPENED TO THIS WHO SOL VRL LOGISTICS AT 300 ON LISTING DAY AND ITS NOW AT 400.

SAME FATE WITH THIS GREAT COMPANY WITH PROFITS OF 175 CRORE.

EVEN THOUGH I WAS ALLOTTED IN IPO I WILL BUY MORE NOW AND KEEP ADDING THIS GROWTH STORY
280.1. gundu anna |   Link |  Bookmark |August 11, 2015 9:38:04 PM (500+ Posts, 100+ Likes)
This is not a real pharma stock, but only contract research service provider.. do not make case for long term investment... they have waited for more than 5 years and wanted good time to sell shows it is not so good for long term investment..
279. sagrawal |   Link |  Bookmark |August 11, 2015 11:17:51 AM
i didn''t received my refund of syngene ipo till date.
What should i do for that
278. patel patel |   Link |  Bookmark |August 11, 2015 11:15:49 AM
MEMBERS HAVE NEW IPO AUGUST MAA CHE
277. Kumaripo |   Link |  Bookmark |August 11, 2015 11:07:36 AM
Sold all the shares @ 310
277.1. patel patel |   Link |  Bookmark |August 11, 2015 11:09:26 AM
GOOD LUCK
277.2. atul |   Link |  Bookmark |August 11, 2015 1:26:52 PM (300+ Posts)
I bought few at 305 and few at 310